We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Tonix Pharmaceuticals is set to develop its TNX-102 SL as a potential therapy for Long COVID syndrome, also known as post-acute sequelae of Covid-19 (PASC).